home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development

 
  April 12, 2024  
     
 
Xtalks, Online
2024-05-02


With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.

What are incretins and how do they really work? How can we better understand their effects and advance drug development in obesity and metabolic disease? What will the future of incretin-based drug development look like?

It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know. In this webinar, the expert speakers will cover how incretins were discovered, what we know about them, current challenges facing incretin drug development and some of the exciting work that is ongoing in this space. They will also discuss how advanced imaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) can give us insights that will help us to better understand incretins, as well as provide relevant information for future drug development.

Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers’ perspectives on the future of incretin drug development.

Keywords: Metabolic Disease, Glucagon, GIP, Incretins, Weight Loss Drug, Clinical Trial Imaging, Muscle Assessment, Diabetes Drug, GLP-1, Body Composition, PET, Weight Loss, Clinical Trials, Imaging, Therapeutic Areas, Medical Imaging, Biomarkers, Type 2 Diabetes, Clinical Research, MRI, Drug Development, Diabetes, Obesity
 
 
Organized by: Xtalks
Invited Speakers: Tina Vilsbøll, MD, DMSc, Professor at Steno Diabetes Centre Copenhagen, University of Copenhagen, Denmark
Michael Wagner, Senior Vice President, Chemistry and Drug Discovery, Dewpoint Therapeutics; Co-Founder, Antaros Tracer
Martin Schain, Director of PET Imaging, Antaros Medical
 
Deadline for Abstracts: 2024-05-02
 
Registration: Free Registration
E-mail: tristan@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.